Topic: amyotrophic lateral sclerosis
Flex Pharma is considering a sale or merger to keep afloat. In the meantime, it has scrapped two midstage trials and is cutting its workforce by 60%.
Aquinnah's new VP of research will head up its discovery efforts for treatments targeting neurodegenerative diseases.
Alnylam is gearing up to move RNAi therapies for central nervous system disorders into the clinic.
Amgen joined with MP Healthcare Venture Management and Alexandria Venture Investments to put the latest tranche of funding into QurAlis.
MediciNova's ibudilast missed its primary endpoint of methamphetamine abstinence in a 12-week phase 2 trial.
Prothena is getting $150 million up front for work on a trio of proteins implicated in neuro diseases.
Cytokinetics canned tirasemtiv after it failed to beat placebo against the primary endpoint or any of the secondary goals in an ALS trial.
Bay Area drug discovery company Verge Genomics has formed industry and academic alliances in neuro disorders.
Targeting a cell process that promotes protein clumping could lead to new drugs for ALS.
AB Science says its drug candidate masitinib has slowed down progression in a late-stage trial, but its checkered development history means the reaction is muted.